Inflammatory Bowel Disease Treatment Market

Inflammatory Bowel Disease Treatment Market Outlook 2031

The Inflammatory Bowel Disease Treatment Market size was USD 20.33 Billion in 2022 and is likely to reach USD 27.95 Billion by 2031, expanding at a CAGR of 3.6% during 2023–2031. The growth of the market is attributed to the presence of huge pipeline products for inflammatory bowel disease treatment.

Inflammatory bowel disease (IBD) is normally caused due to the attack by immune system on harmless virus, bacteria, or food present inside the intestine. Crohn’s disease, and ulcerative colitis are two most common types of IBD. The IBD drugs are used to treat autoimmune diseases include indeterminate colitis, ulcerative colitis, and Crohn’s disease.

Get Free Sample Report

Crohn’s disease affects any part of GI tract and ulcerative colitis affects the anus and the large intestine which causes inflammation in the rectum and colon. Inflammatory bowel disease symptoms are caused due to change in lifestyle, autoimmune disorders, and genetic factors. The common symptoms of IBD are abdominal pain & cramps, rectal bleeding, fever, diarrhea, weight loss, and constipation.

Emergence of biosimilars is a key factor responsible for aiding the market expansion. Biosimilars are cheaper than biologics. Hence, biosimilars are largely available in emerging countries. Patent expiration of some drugs is propelling the launch of novel biosimilars. For instance, the Food and Drug Administration (FDA), in 2016, approved Inflectra, which was a biosimilar with lower cost. It is similar to Remicade. Remicade is manufactured by Janssen Non-surgical and used to treat Crohn’s disease and ulcerative colitis.

Key market players such as Celgene, Shire, Eli Lilly and Company, Gilead Sciences, AbbViee Inc., and Pfizer Inc. are focusing on R&D for commercializing and launching improved version of existing products. Also, Risankizumab, Upadacitinib, and Ozanimod are some pipeline products which are projected to have enhanced mechanism of efficiency and action.

Inflammatory Bowel Disease Treatment Market Trends, Drivers, Restraints, and Opportunities

• Growing geriatric population and increasing prevalence of Crohn's disease and ulcerative colitis are anticipated to boost the market growth.
• Increasing government support for research into IBD and rising ubiquity of anxiety and depression are projected to drive the growth of the market.
• Rising number of drugs in clinical trials and increasing participation of regulatory bodies for funding and designation are expected to fuel the market expansion in coming years.
• Advancement in medical technology and increasing acceptance of pre-biotic and pro-biotic foods are major factors responsible for propelling the market growth over the forecast period.
• Stringent regulations, huge capital investments required for drug discovery, and inadequate effectiveness of treatment are expected to impede the market growth over the forecast period.

Scope of The Inflammatory Bowel Disease Treatment Market Report

The report on the global inflammatory bowel disease treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Inflammatory Bowel Disease Treatment Market Segment Insights

Ulcerative colitis segment is expected to expand at a rapid pace

Based on types, the inflammatory bowel disease treatment market is segmented into Crohn’s disease and ulcerative colitis. The Crohn’s disease segment is expected to hold a key share of the market during the forecast period owing to growing prevalence of the condition.

• Based on article, published by the Jobson Medical Information LLC, in 2018, every year the prevalence of Crohn’s disease was found around 200 cases per 100,000 person in the U.S.

On the other hand, the ulcerative colitis segment is anticipated to expand at a rapid pace during the forecast period due to huge presence of pipeline products for the treatment. Also, rising involvement of major market players in development of products is projected to fuel the segment growth.

Get Free Sample Report

Injectables segment is projected to hold a key market share

On the basis of routes of administration, the inflammatory bowel disease treatment market is divided into injectables and oral. The injectables segment is further subdivided into TNF-inhibitors, IL inhibitors, anti-integrin, and others. The injectables segment is expected to account for a key share of the market in the coming years due to their efficacy. Addition to this, emergence of biosimilars such as Inflectra is projected to drive the growth of the segment. In 2018, TNF-inhibitors was the major sub-segment.

However, the oral segment is anticipated to expand at a rapid pace during the forecast period owing to huge presence of pipeline products. The oral segment is subdivided into ASAs, corticosteroids, JAK inhibitors, and others. The market was dominated by ASAs and JAK inhibitors is expected to expand at a significant pace during the forecast period.

Online pharmacy segment is expected to grow at a significant pace

In terms of distribution channels, the market is bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment is expected to represent a key share of the market in the coming years. Growing prevalence of ulcerative colitis and Crohn’s disease result in increasing number of hospitalizations across globe.

On the other hand, the online pharmacy segment is anticipated to expand at a rapid pace during the forecast period. The online purchasing trend and demand is increasing because of convenience, comfort and flexibility. Due to this generation of revenue is increasing. Also, online shopping offers several discounts which is expected to boost the segment growth.

North America is expected to dominate the market

On the basis of regions, the inflammatory bowel disease treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to presence of major market players and well-established healthcare infrastructure.

Moreover, growing geriatric population and prevalence of Crohn’s disease and ulcerative colitis are expected to drive the regional market growth. Based on study published in the NCBI in 2019, the incidence of IBD treatment in the North America is approximately 2 to 19 cases per 100,000 person every year. Also, in the U.S., around 240 per 100,000 population were suffering from ulcerative colitis. The market of Asia Pacific is expected to exhibit a rapid growth rate during the forecast period owing to increasing product approvals.

Get Free Sample Report

Segments

The global inflammatory bowel disease treatment market has been segmented on the basis of

Types

• Ulcerative Colitis
• Crohn’s Disease

Routes of Administration

• Injectables
  • TNF-inhibitors
  • IL inhibitors
  • Anti-integrin
  • Others
• Oral
  • ASAs
  • Corticosteroids
  • JAK inhibitors
  • Others

Distribution Channels

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Regions

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Johnson & Johnson Services Inc.
• Pfizer Inc.
• Takeda Pharmaceutical Company Limited
• AbbVie Inc.
• Celltrion Healthcare Co., Ltd.
• CELGENE CORPORATION
• COSMO PHARMACEUTICALS
• Innovate Biopharmaceuticals
• UCB S.A.
• Gilead Sciences

Competitive Landscape

Key players competing in the inflammatory bowel disease treatment market include Johnson & Johnson Services Inc., Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Celltrion Healthcare Co., Ltd., CELGENE CORPORATION, COSMO PHARMACEUTICALS, Innovate Biopharmaceuticals, UCB S.A., and Gilead Sciences.

Major market players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For instance, Janssen Biotech, Inc., in 2017, collaborated with Protagonist Therapeutics Inc. for development, manufacture, and market PTG-200. PTG-200 was an oral IL 23 receptor for IBD treatment.